Test your knowledge of hemophagocytic lymphohistiocytosis following CAR T-cell therapy in a patient with multiple myeloma

What was the primary reason for evaluating the patient for CAR T-cell therapy?
Failure to respond to initial CyBorD therapy
Disease progression at day 180 post autologous stem cell transplant
Development of cytokine release syndrome
Cytogenetic abnormalities (1p1q)
Which complication prompted the initiation of anakinra and dexamethasone on day 7 post-CAR T-cell infusion?
Cytokine release syndrome (CRS)
Immune effector cell–associated neurotoxicity syndrome (ICANS)
Hemophagocytic lymphohistiocytosis (HLH)
Neutropenic fever
Which of the following therapies was used as bridging therapy before the CAR T-cell infusion?
Daratumumab plus lenalidomide, bortezomib, and dexamethasone (Dara + RVD)
Cyclophosphamide, bortezomib, and dexamethasone (CyBorD)
Carfilzomib, cyclophosphamide, and dexamethasone
Melphalan 200 mg/m²
0
{"name":"Test your knowledge of hemophagocytic lymphohistiocytosis following CAR T-cell therapy in a patient with multiple myeloma", "url":"https://www.quiz-maker.com/Q0GPCGNNR","txt":"What was the primary reason for evaluating the patient for CAR T-cell therapy?, Which complication prompted the initiation of anakinra and dexamethasone on day 7 post-CAR T-cell infusion?, Which of the following therapies was used as bridging therapy before the CAR T-cell infusion?","img":"https://www.quiz-maker.com/3012/images/ogquiz.png"}
Tools: Poll Maker | Quiz Maker | Super Survey Maker